| Combination therapies using cd-38 antibodies A Palumbo, K Allikmets, D Berg, E Fedyk US Patent App. 17/617,811, 2022 | | 2022 |
| Subcutaneous administration of anti-cd38 antibodies M Dahl, E Fedyk, R Evans, L Zhao US Patent App. 16/961,346, 2021 | | 2021 |
| A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects E Esfandiari, M Chen, G Smithson, D Blair, H Faessel, J Wagner, ... Clinical and Translational Science 14 (3), 820-828, 2021 | 4 | 2021 |
| Subcutaneous dosing of anti-cd38 antibodies E Fedyk, M Hanley, A Palumbo US Patent App. 17/041,783, 2021 | | 2021 |
| Subcutaneous dosing of anti-cd38 antibodies E FEDYK, M Hanley, A Palumbo | | 2021 |
| métodos para tratar uma doença em um sujeito e para tratar um câncer hematológico em um sujeito, e, forma farmacêutica unitária. E Fedyk, M Hanley, A PALUMBO | | 2021 |
| Combination therapies using cd-38 antibodies A Palumbo, K ALLIKMETS, B Deborah, E FEDYK | | 2020 |
| Dosagem subcutânea de anticorpos anti-cd38 M Dahl, E Fedyk, R Evans, L Zhao | | 2020 |
| Dosificación subcutánea de anticuerpos anti-cd38 E Fedyk, M Hanley, A Palumbo | | 2020 |
| Mezagitamab induces immunomodulatory effect in patients with relapsed/refractory multiple myeloma (RRMM) M Abadier, J Estevam, D Berg, ER Fedyk Blood 136, 9, 2020 | 2 | 2020 |
| Dosificación subcutánea de anticuerpos anti-cd38 M Dahl, E Fedyk, R Evans, L Zhao | | 2020 |
| Subcutaneous dosing of anti-CD38 antibodies M Dahl, R Evans, E FEDYK, L Zhao AU Patent App. 2,019,208,102 A, 2020 | | 2020 |
| Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects ER Fedyk, L Zhao, A Koch, G Smithson, J Estevam, G Chen, G Lahu, ... British Journal of Clinical Pharmacology 86 (7), 1314-1325, 2020 | 28 | 2020 |
| Preliminary results from a phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM) AY Krishnan, KK Patel, P Hari, S Jagannath, R Niesvizky, RW Silbermann, ... Blood 134, 140, 2019 | 29 | 2019 |
| The binding of CD38 therapeutics to red blood cells and platelets subverts depletion of target cells ER Fedyk, N Idamakanti, J Chen, J Estevam, V Hernandez, M Wagoner, ... Blood 134, 3136, 2019 | 2 | 2019 |
| Subcutaneous dosing of anti-cd38 antibodies E FEDYK, M Hanley, A Palumbo | | 2019 |
| A reduction in B, T, and natural killer cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys W Korver, M Carsillo, J Yuan, N Idamakanti, M Wagoner, P Shi, CQ Xia, ... Journal of Pharmacology and Experimental Therapeutics 370 (2), 182-196, 2019 | 26 | 2019 |
| Subcutaneous dosing of anti-cd38 antibodies M Dahl, E FEDYK, R Evans, L Zhao | | 2019 |
| A single administration of the cytolytic CD38 antibody TAK-079 to healthy subjects: Tolerability, pharmacokinetics and pharmacodynamics ER Fedyk, D Berg, G Smithson, J Estevam, L Mclean, K Allikmets, ... Blood 132, 3249, 2018 | 7 | 2018 |
| MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model K Igaki, Y Komoike, Y Nakamura, T Watanabe, M Yamasaki, P Fleming, ... International immunopharmacology 60, 160-169, 2018 | 21 | 2018 |
